A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
Women's Health Trial Tracker organizes records from ClinicalTrials.gov API v2 into a static table for transparent comparison. It preserves official source links and dates, marks missing enrichment, and adds deterministic grouping, change, recency, trend, or significance fields only where the documented inputs support them, without recommendations or unsupported claims.
- Title
- A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
- Record Date
- 08/21/2023
- Vuga Group
- INTERVENTIONAL
- Change Status
- unchanged
- Recency Days
- 1,101.85
- Public Significance Score
- 0